The China Securities Regulatory Commission has approved Hanbang Technology's initial public offering (IPO) registration on the Shanghai Stock Exchange's Science and Technology Innovation Board.

On March 6, the China Securities Regulatory Commission approved the registration of Jiangsu Hanbang Technology Co., Ltd.'s initial public offering. It is reported that Hanbang Technology plans to list on the Science and Technology Innovation Board of the Shanghai Stock Exchange, with CITIC Securities as the sponsor, and plans to raise RMB598 million. The prospectus reveals that Hanbang Technology is a high-tech enterprise integrating R&D, production, and sales, with chromatography technology as its core, dedicated to "purifying chromatography technology and contributing to human health", and striving to "establish the first brand in the international chromatography industry", mainly providing professional separation and purification equipment, consumables, application services, and related technical solutions for the pharmaceutical, life sciences, and other fields. The funds raised by the Company will be invested in the production of 1,000 units of liquid chromatography series separation equipment, the chromatography separation equipment R&D center project, and the production of 2,000 units (sets) of laboratory chromatography separation and purification instruments, which will help the Company increase its R&D investment, expand its production scale, continuously enhance the competitiveness of its core products, and achieve long-term healthy development. In recent years, Hanbang Technology has relied on its comprehensive product layout and leading customer service capabilities to respond to downstream market demand for various equipment products in a timely manner and actively expand overseas markets, and has already formed a drug separation and purification equipment product with industry competitiveness.